PMID- 17197564
OWN - NLM
STAT- MEDLINE
DCOM- 20070205
LR  - 20181201
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 48
IP  - 1
DP  - 2007 Jan
TI  - Neurotrophic factors minimize the retinal toxicity of verteporfin photodynamic 
      therapy.
PG  - 430-7
AB  - PURPOSE: A prior study showed that brain-derived neurotrophic factor (BDNF) 
      rescues photoreceptors from collateral retinal damage caused by photodynamic 
      therapy (PDT). This study was conducted to determine whether ciliary neurotrophic 
      factor (CNTF), a combination of BDNF and CNTF, or pigment epithelial cell-derived 
      growth factor (PEDF) might protect photoreceptors and retinal function more 
      effectively than BDNF. Also investigated was whether protection would be observed 
      after a second round of PDT with adjunctive BDNF treatment. METHODS: Normal rats 
      received intravitreal injections of BDNF, CNTF, a combination of BDNF and CNTF, 
      or PEDF in one eye and PBS in the other 2 days before PDT. Retinal function and 
      photoreceptor survival were assessed with multifocal ERG (mfERG) and histology 1 
      week after PDT. Another group of rats received two courses of PDT 3 months apart, 
      with injection of BDNF 2 days before each treatment. RESULTS: All factors 
      significantly increased photoreceptor survival. The combination of BDNF and CNTF 
      rescued more photoreceptors than either factor alone. Only BDNF improved retinal 
      function 1 week after PDT, with CNTF and the combination of BDNF and CNTF 
      reducing mfERG responses. BDNF injection before a second round of PDT improved 
      mfERG responses and retinal structure. CONCLUSIONS: BDNF is the most effective 
      single factor among those tested for neuroprotection and improvement of retinal 
      function after PDT, although a combination of BDNF and CNTF rescues more 
      photoreceptors. Adjunctive treatment with BDNF also protects retinal structure 
      and function through two rounds of PDT, suggesting its potential value for 
      patients who require multiple treatments.
FAU - Paskowitz, Daniel M
AU  - Paskowitz DM
AD  - Department of Ophthalmology, University of California, San Francisco, California 
      94143, USA.
FAU - Donohue-Rolfe, Kate M
AU  - Donohue-Rolfe KM
FAU - Yang, Haidong
AU  - Yang H
FAU - Yasumura, Douglas
AU  - Yasumura D
FAU - Matthes, Michael T
AU  - Matthes MT
FAU - Hosseini, Kamran
AU  - Hosseini K
FAU - Graybeal, Carolyn M
AU  - Graybeal CM
FAU - Nune, George
AU  - Nune G
FAU - Zarbin, Marco A
AU  - Zarbin MA
FAU - Lavail, Matthew M
AU  - Lavail MM
FAU - Duncan, Jacque L
AU  - Duncan JL
LA  - eng
GR  - EY00415/EY/NEI NIH HHS/United States
GR  - EY01919/EY/NEI NIH HHS/United States
GR  - EY02162/EY/NEI NIH HHS/United States
GR  - EY06842/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Ciliary Neurotrophic Factor)
RN  - 0 (Eye Proteins)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
RN  - 0 (Serpins)
RN  - 0 (pigment epithelium-derived factor)
RN  - 0X9PA28K43 (Verteporfin)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/therapeutic use
MH  - Cell Survival/drug effects
MH  - Ciliary Neurotrophic Factor/therapeutic use
MH  - Drug Therapy, Combination
MH  - Electroretinography/drug effects
MH  - Eye Proteins/therapeutic use
MH  - Injections
MH  - Nerve Growth Factors/*therapeutic use
MH  - Neuroprotective Agents/*therapeutic use
MH  - *Photochemotherapy
MH  - Photoreceptor Cells, Vertebrate/*drug effects/pathology
MH  - Photosensitizing Agents/*toxicity
MH  - Porphyrins/*toxicity
MH  - Rats
MH  - Rats, Inbred BN
MH  - Retina/drug effects/physiology
MH  - Retinal Diseases/chemically induced/physiopathology/*prevention & control
MH  - Serpins/therapeutic use
MH  - Verteporfin
MH  - Vitreous Body
EDAT- 2007/01/02 09:00
MHDA- 2007/02/06 09:00
CRDT- 2007/01/02 09:00
PHST- 2007/01/02 09:00 [pubmed]
PHST- 2007/02/06 09:00 [medline]
PHST- 2007/01/02 09:00 [entrez]
AID - 48/1/430 [pii]
AID - 10.1167/iovs.06-0690 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2007 Jan;48(1):430-7. doi: 10.1167/iovs.06-0690.